Senti Biosciences Holdings
SNTI
16 hedge funds and large institutions have $8.27M invested in Senti Biosciences Holdings in 2025 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 4 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
7% more funds holding
Funds holding: 15 → 16 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.42% less ownership
Funds ownership: 25.84% → 22.41% (-3.4%)
42% less capital invested
Capital invested by funds: $14.2M → $8.27M (-$5.95M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$426K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$138K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$44.4K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$27.3K |
| 5 |
Two Sigma Investments
New York
|
+$26.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.88M |
| 2 |
HCM
Heights Capital Management
San Francisco,
California
|
-$805K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$9.31K |
| 4 |
Barclays
London,
United Kingdom
|
-$1.2K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$179 |
SNTI Hedge Fund Activity: Q3 2025 in Review
16 of the 7,635 institutional investors tracked by Wall St. Rank reported a position in Senti Biosciences Holdings (SNTI) for Q3 2025, worth a combined $8.27M — down 42% from $14.2M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new SNTI positions and 4 closed out — a net gain of 1 holder — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Vanguard Group, adding an estimated $426K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.88M sold.
- 16 institutional investors held Senti Biosciences Holdings (SNTI) as of Q3 2025, up from 15 in Q2 2025.
- Funds reported $8.27M of Senti Biosciences Holdings stock for Q3 2025, down 42% quarter-over-quarter.
- 5 funds opened new Senti Biosciences Holdings positions in Q3 2025 and 4 closed out, a net change of +1 holder.
- The largest Senti Biosciences Holdings buyer in Q3 2025 was Vanguard Group, an estimated $426K added.
- The largest Senti Biosciences Holdings seller in Q3 2025 was Armistice Capital, an estimated $1.88M sold.
Based on aggregated 13F filings for Q3 2025.